miR-223: Infection, inflammation and cancer
Citation:
Haneklaus, M., Gerlic, M., O'Neill, L.A.J., Masters, S.L., miR-223: Infection, inflammation and cancer, Journal of Internal Medicine, 274, 3, 2013, 215-226Download Item:
Abstract:
Expression of the microRNA miR-223 is deregulated during influenza or hepatitis B infection and in inflammatory bowel disease, type 2 diabetes, leukaemia and lymphoma. Although this may also be the result of the disease per se, increasing evidence suggests a role for miR-223 in limiting inflammation to prevent collateral damage during infection and in preventing oncogenic myeloid transformation. Validated targets for miR-223 that have effects on inflammation and infection include granzyme B, IKKα, Roquin and STAT3. With regard to cancer, validated targets include C/EBPβ, E2F1, FOXO1 and NFI-A. The effect of miR-223 on these targets has been documented individually; however, it is more likely that miR-223 affects multiple targets simultaneously for key processes where the microRNA is important. Such processes include haematopoietic cell differentiation, particularly towards the granulocyte lineage (where miR-223 is abundant) and as cells progress down the myeloid lineage (where miR-223 expression decreases). NF-κB and the NLRP3 inflammasome are important inflammatory mechanisms that are dampened by miR-223 in these cell types. The miRNA can also directly target viruses such as HIV, leading to synergistic effects during infection. Here we review the recent studies of miR-223 function to show how it modulates inflammation, infection and cancer development.
Sponsor
Grant Number
Science Foundation Ireland (SFI)
Author's Homepage:
http://people.tcd.ie/laoneillDescription:
PUBLISHED
Author: O'NEILL, LUKE
Type of material:
Journal ArticleCollections
Series/Report no:
Journal of Internal Medicine274
3
Availability:
Full text availableKeywords:
ImmunologySubject (TCD):
Cancer , Immunology, Inflammation & InfectionDOI:
http://dx.doi.org/10.1111/joim.12099Metadata
Show full item recordLicences: